Morgan Stanley Acurx Pharmaceuticals, Inc. Put Options Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ACXP
# of Institutions
34Shares Held
2.59MCall Options Held
62.9KPut Options Held
56.9K-
Armistice Capital, LLC New York, NY1.08MShares$5.46 Million0.01% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$1.85 Million0.08% of portfolio
-
Geode Capital Management, LLC Boston, MA146KShares$740,8040.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA146KShares$736,4170.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny87.8KShares$444,1710.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $58.5M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...